Pradaxa 150mg BiD administration is extended.

Antiphospholipid antibody syndrome is a risk factor for recurrent thrombosis in patients with unprovoked PE.

Extended use of anticoagulation can be considered and risk-benefit ratio needs to be regularly re-assessed (IC classification). 

What should the doctor do?